Search Results - "Van Oene, J. C."

Refine Results
  1. 1

    Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study by Diener, H-C, Bussone, G, Van Oene, J C, Lahaye, M, Schwalen, S, Goadsby, P J

    Published in Cephalalgia (01-07-2007)
    “…The aim of this study was to evaluate the efficacy and tolerability of topiramate for the prevention of chronic migraine in a randomized, double-blind,…”
    Get more information
    Journal Article
  2. 2

    Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate by Buitelaar, J K, Casas, M, Philipsen, A, Kooij, J J S, Ramos-Quiroga, J A, Dejonckheere, J, van Oene, J C, Schäuble, B

    Published in Psychological medicine (01-01-2012)
    “…Data on the relationship between core symptoms and daily functioning in adults with attention deficit hyperactivity disorder (ADHD) are limited. Daily…”
    Get more information
    Journal Article
  3. 3

    Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation by Sloots, C. E. J., Poen, A. C., Kerstens, R., Stevens, M., De Pauw, M., Van Oene, J. C., Meuwissen, S. G. M., Felt‐Bersma, R. J. F.

    Published in Alimentary pharmacology & therapeutics (01-04-2002)
    “…Background: There is a need for better tolerated drugs to normalize bowel function in chronic constipation. Prucalopride is a highly selective, specific,…”
    Get full text
    Journal Article
  4. 4

    The influence of cisapride and clarithromycin on QT intervals in healthy volunteers by Haarst, Aernout D., van't Klooster, Gerben A. E., Gerven, Joop M. A., Schoemaker, Rik C., Oene, Joop C., Burggraaf, Jacobus, Coene, Marie‐Claire, Cohen, Adam F.

    Published in Clinical pharmacology and therapeutics (01-11-1998)
    “…Objective Recently a few cases of long QT syndrome were reported during treatment with cisapride. In most of these cases, risk factors for cardiac arrhythmias…”
    Get full text
    Journal Article
  5. 5
  6. 6

    [125I]SCH 23982: the ligand of choice for identifying the D-1 dopamine receptor by Sidhu, A, van Oene, J C, Dandridge, P, Kaiser, C, Kebabian, J W

    Published in European journal of pharmacology (09-09-1986)
    “…[125I]SCH 23982, [125I]8-iodo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7-ol, binds reversibly and with high affinity (Kd = 0.7 +/- 0.05 nM) to…”
    Get more information
    Journal Article
  7. 7

    Effect of ketanserin on intraoperative blood loss during total hip arthroplasty in elderly patients under general anaesthesia by van EE, R, van Oene, J C

    Published in British journal of anaesthesia : BJA (01-04-1991)
    “…We have studied the effect of ketanserin, a selective serotonin S2-receptor antagonist, on surgical bleeding in a double-blind, placebo-controlled study in…”
    Get more information
    Journal Article
  8. 8

    Standard‐dose lansoprazole is more effective than high‐dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis by JANSEN, J. B. M. J, VAN OENE, J. C

    Published in Alimentary pharmacology & therapeutics (01-12-1999)
    “…Background: In the treatment of reflux oesophagitis, H2‐receptor antagonists are still widely used in spite of the apparent higher efficacy of proton pump…”
    Get full text
    Journal Article
  9. 9

    Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy by KUNNEN, J. J, DAHLER, H. P, DOORENSPLEET, J. G, VAN OENE, J. C

    “…The severity of the peripheral vasopastic condition in 10 patients with Raynaud's phenomenon was investigated using scintigraphy of both hands…”
    Get full text
    Journal Article
  10. 10

    Ketanserin pharmacokinetics in patients with renal failure by Barendregt, JN, Peer, A, Hoeven, JG, Oene, JC, Tjandra, YI

    Published in British journal of clinical pharmacology (01-06-1990)
    “…1. The pharmacokinetics of ketanserin and its major metabolite ketanserin‐ol were investigated after a single oral dose of 40 mg and after chronic oral…”
    Get full text
    Journal Article
  11. 11

    In vivo dopamine autoreceptor selectivity appears to be critically dependent upon the aromatic hydroxyl position in a series of N,N-disubstituted 2-aminotetralins by Van Oene, J C, De Vries, J B, Dijkstra, D, Renkema, R J, Tepper, P G, Horn, A S

    Published in European journal of pharmacology (15-06-1984)
    “…The potencies of a number of 2-aminotetralin derivatives as centrally acting dopamine (DA) receptor agonists were investigated using the reversal of the…”
    Get more information
    Journal Article
  12. 12

    The purported dopamine agonist DPI inhibits [3H]noradrenaline release from rat cortical slices but not [3H]dopamine and [14C]acetylcholine release from rat striatal slices in-vitro by Van Oene, J C, Sminia, P, Mulder, A H, Horn, A S

    Published in Journal of pharmacy and pharmacology (01-12-1983)
    “…The effects of the purported dopamine (DA) receptor agonist (3,4-dihydroxyphenylimino)-2-imidazolidine (DPI) upon the in-vitro K+-induced release of [3H]DA and…”
    Get more information
    Journal Article
  13. 13
  14. 14

    Oral dosing with ketanserin to control high blood pressure in the elderly by VAN OENE, J. C

    Published in Cardiovascular drugs and therapy (1990)
    “…Ketanserin is the prototype of a new class of antihypertensive drugs based on a selective blockade of serotonin S2 receptors. A number of controlled trials…”
    Get full text
    Conference Proceeding Journal Article
  15. 15

    The effectiveness of yohimbine in blocking rat central dopamine autoreceptors in vivo by VAN OENE, J. C, DE VRIES, J. B, HORN, A. S

    “…The influence of various alpha-adrenoceptor antagonists (10 mg/kg i.p.) upon the rate of turnover of dopamine (DA) in the rat brain was investigated. Taking…”
    Get full text
    Journal Article
  16. 16

    3,4-disubstituted phenyliminoimidazolidines as potential prodrugs of the purported dopamine agonist 3,4-dihydroxyphenylimino-2-imidazolidine (DPI) by Houwing, H A, van Oene, J C, Horn, A S

    “…A series of ether derivatives of the purported dopamine agonist 3,4-dihydroxyphenylimino-2-imidazolidine (DPI) has been prepared as potential prodrugs of the…”
    Get more information
    Journal Article
  17. 17

    Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group by Jansen, J B, Van Oene, J C

    Published in Alimentary pharmacology & therapeutics (01-12-1999)
    “…In the treatment of reflux oesophagitis, H2-receptor antagonists are still widely used in spite of the apparent higher efficacy of proton pump inhibitors. In…”
    Get full text
    Journal Article
  18. 18

    The purported dopamine agonist (3,4-dihydroxyphenylimino)-2-imidazolidine (DPI) acts as a nonselective alpha-adrenoceptor agonist in inducing hypertension, hypomotility and hypothermia in the rat by Van Oene, J C, Houwing, H A, Horn, A S

    Published in European journal of pharmacology (05-11-1982)
    “…Following peripheral administration the purported dopamine (DA) agonist (3,4-dihydroxyphenylimino)-2-imidazolidine (DPI) was shown to increase the diastolic…”
    Get more information
    Journal Article
  19. 19

    trans-N-n-Propyl-7-hydroxy-octahydrobenzo(f)quinoline, a rigid 3-PPP analogue with greater potency but lack of selectivity for dopamine autoreceptors by Van Oene, J C, Houwing, H A, Dijkstra, D, Horn, A S

    Published in European journal of pharmacology (04-03-1983)
    “…trans- and cis-7-hydroxy-octahydrobenzo(f)quinoline were synthesized as analogues of the selective dopamine autoreceptor agonist 3-PPP. The trans compound…”
    Get more information
    Journal Article
  20. 20

    Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial by Serruys, P W, Klein, W, Tijssen, J P, Rutsch, W, Heyndrickx, G R, Emanuelsson, H, Ball, S G, Decoster, O, Schroeder, E, Liberman, H

    Published in Circulation (New York, N.Y.) (01-10-1993)
    “…Ketanserin is a serotonin S2-receptor antagonist that inhibits the platelet activation and vasoconstriction induced by serotonin and also inhibits the…”
    Get full text
    Journal Article